Zanubrutinib + Bendamustine + Rituximab + Venetoclax
Phase 3Active 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Chronic Lymphocytic Leukemia
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Trial Timeline
Oct 31, 2017 → Oct 31, 2027
NCT ID
NCT03336333About Zanubrutinib + Bendamustine + Rituximab + Venetoclax
Zanubrutinib + Bendamustine + Rituximab + Venetoclax is a phase 3 stage product being developed by BeOne Medicines for Chronic Lymphocytic Leukemia. The current trial status is active. This product is registered under clinical trial identifier NCT03336333. Target conditions include Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03336333 | Phase 3 | Active |
Competing Products
20 competing products in Chronic Lymphocytic Leukemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| macitentan 10 mg | BML, Inc. | Phase 3 | 76 |
| KPL-716 + Placebo | Kiniksa Pharmaceuticals | Phase 2 | 47 |
| TERN-701 | Terns Pharmaceuticals | Phase 1/2 | 38 |
| Fludarabine + Cyclophosphamide + PRGN-3007 | Precigen | Phase 1 | 28 |
| LY3556050 + Placebo | Eli Lilly | Phase 2 | 52 |
| THB001 | Third Harmonic Bio | Phase 1 | 25 |
| Briquilimab | Jasper Therapeutics | Phase 1/2 | 33 |
| Briquilimab | Jasper Therapeutics | Phase 1/2 | 33 |
| Briquilimab | Jasper Therapeutics | Phase 2 | 44 |
| Empagliflozin + Matching placebo | Eli Lilly | Phase 3 | 77 |
| LY3461767 + Placebo | Eli Lilly | Phase 1 | 33 |
| Pirtobrutinib + Venetoclax + Rituximab | Eli Lilly | Phase 3 | 77 |
| LY3526318 + Placebo | Eli Lilly | Phase 2 | 52 |
| Pirtobrutinib | Eli Lilly | Phase 2 | 52 |
| Ibrutinib + LY3214996 | Eli Lilly | Phase 1 | 33 |
| Pirtobrutinib + Acalabrutinib | Eli Lilly | Phase 2 | 52 |
| LYR-210 | Lyra Therapeutics | Phase 2 | 44 |
| LYR-220 Design 1 (Part 1 only) + LYR-220 Design 2 (Part 1 and Part 2) + Bilateral sham procedure control (Part 2) | Lyra Therapeutics | Phase 2 | 44 |
| 480 Mometasone Furoate Sinus Drug Depot | Lyra Therapeutics | Phase 1 | 25 |
| LYR-210 + Sham procedure control | Lyra Therapeutics | Phase 3 | 69 |
Other Products from BeOne Medicines
ZanubrutinibApproved
82
Tislelizumab + Pamiparib + Temozolomide + Sitravatinib + Ociperlimab + BAT1706 + Fruquintinib + BGB-15025 + Zanidatamab + BGB-A445 + Surzebiclimab + Lenvatinib + LBL-007Phase 3
74
Zanidatamab + Tislelizumab + Trastuzumab + Capecitabine + Oxaliplatin + Cisplatin + 5-FluorouracilPhase 3
74
Tislelizumab + Placebo + Cisplatin + Gemcitabine Hydrochloride + CarboplatinPhase 3
74
Sonrotoclax + Zanubrutinib + PlaceboPhase 3
74